Skip to main content

Table 2 Antimicrobial resistance of E. faecium and E. faecalis

From: Drug-resistant and hospital-associated Enterococcus faecium from wastewater, riverine estuary and anthropogenically impacted marine catchment basin

 

Number (%) of isolates

 

Resistant to a single antimicrobial agent

Sensitive

MDR phenotype

 

GM

ST

AM

CIP

LVX

TE

SYN

E

S

 

E. faecium n = 244

W = INF (n = 19)

1 (5.3)

3 (15.8)

1 (5.3)

6 (31.6)

1 (5.3)

5 (26.3)

6 (31.6)

7 (36.8)

6 (31.6)

4 (21.1)

W-BR (n = 36)

1 (2.8)

2 (5.6)

1 (2.8)

12 (33.2)

3 (8.3)

7 (19.4)

19 (52.8)

16 (44.4)

10 (27.8)

8 (22.2)

W-EFF (n = 53)

3 (5.7)

2 (3.8)

4 (7.5)

23 (43.4)

10 (18.9)

10 (18.9)

18 (34.0)

24 (45.3)

12 (22.6)

14 (26.4)

W-MOut (n = 29)

0

6 (20.7)

6 (20.7)

13 (44.8)

4 (13.8)

8 (27.6)

14 (48.3)

17 (58.6)

5 (17.4)

9 (31.0)

D-EFF (n = 41)

1 (2.4)

6 (14.6)

5 (12.2)

13 (31.7)

2 (4.9)

10 (24.4)

12 (29.2)

28 (68.2)

4 (9.8)

8 (19.5)

D-MOut (n = 40)

1 (2.5)

2 (5)

2 (5)

14 (35.0)

3 (7.5)

2 (5.0)

21 (52.5)

22 (55.0)

7 (17.5)

3 (7.5)

VR (n = 26)

0

1 (3.8)

0

8 (30.8)

1 (3.8)

2 (7.7)

15 (57.7)

11 (42.4)

3 (11.5)

3 (11.5)

All (n = 244)

7 (2.9)

22 (9.0)

19 (7.8)

90 (36.9)

24 (9.8)

44 (18.0)

105 (43.0)

125 (51.2)

49 (20.1)

47 (19.3)

E. faecalis n = 63

W-INF (n = 5)

0

1 (20.0)

0

1 (20.0)

0

1 (20.0)

na

1 (20.0)

4 (80.0)

0

W-BR (n = 8)

2 (25.0)

2 (25.0)

1 (12.5)

2 (25.0)

2 (25.0)

2 (25.0)

na

7 (87.5)

1 (12.5)

2 (25.0)

W-EFF (n = 19)

0

1 (5.3)

1 (5.3)

3 (15.8)

3 (15.8)

4 (21.1)

na

13 (68.4)

0

3 (15.8)

W-MOut (n = 4)

0

0

0

0

0

0

na

4 (100)

0

0

D-EFF (n = 19)

2 (10.5)

5 (26.3)

0

1 (5.3)

0

9 (47.4)

na

13 (68.4)

4 (21.1)

5 (26.3)

D-MOut (n = 3)

1 (33.3)

1 (33.3)

0

0

0

2 (66.7)

na

2 (66.7)

0

1 (33.3)

VR (n = 5)

0

0

0

2 (40.0)

0

0

na

1 (20.0)

2 (40.0)

0

All (n = 63)

5 (7.9)

10 (15.9)

2 (3.2)

9 (14.3)

5 (7.9)

18 (28.6)

na

41 (65.1)

11 (17.5)

11 (17.5)

  1. GM, gentamicin; ST, streptomycin; AM, ampicillin; CIP, ciprofloxacin; LVX, levofloxacin; TE, tetracycline; SYN, quinupristin-dalfopristin; E, erythromycin; S, sensitive to all tested antimicrobial agents; MDR, multiple drug resistance; na, not applicable.
  2. Abbreviations of sampling points’ locations and their description provided in Figure 1.